The Motley Fool··James HalleyAbbott Laboratories Positions as Dividend Growth Play Amid Diagnostic Headwinds
Abbott maintains 54-year dividend streak with 10% EPS growth projected for 2026, despite near-term diagnostic headwinds and manufacturing challenges offsetting strategic acquisitions and FDA approvals.
ABTEXASTLRYacquisitionhealthcare